GlassScriptPhysician profile
Matthew D Prine
NPI 1558650861
$15,065.12
in general payments reported to CMS, 2019-2025
53 companies · $2,408 in 2025
The $2,408 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,786 · 2020: $1,842 · 2021: $2,096 · 2022: $1,858 · 2023: $1,903 · 2024: $2,172 · 2025: $2,408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,442 · Education: $40.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,442.23 |
| Education | $40.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,273.86 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $1,759.85 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,651.32 | 2019-2025 | Xarelto, Invega Sustenna |
| Astrazeneca Pharmaceuticals LP | $1,330.90 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $830.35 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $823.47 | 2019-2025 | Relistor, Xifaxan |
| Glaxosmithkline, LLC. | $693.39 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $574.53 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $440.27 | 2021-2025 | Verquvo, Gardasil 9, Capvaxive |
| Teva Pharmaceuticals USA, INC. | $416.49 | 2020-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $407.75 | 2023-2025 | Rexulti, Nuedexta |
| Novo Nordisk INC | $338.06 | 2019-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $337.61 | 2019-2025 | Jardiance, Synjardy |
| Takeda Pharmaceuticals U.S.A., INC. | $294.37 | 2019-2025 | Trintellix |
| Sumitomo Pharma America, INC. | $285.12 | 2024-2025 | Gemtesa, Myfembree |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Prine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.